Impact of delaying PCV20 implementation in France’s pediatric national immunization program: A population-based Markov model - 24/07/25
, Stéphane Fiévez cHighlights |
• | PCV20 prevents more disease cases and deaths than PCV13 or PCV15 in 2 years. |
• | Delayed PCV20 implementation increases cases, deaths, and healthcare costs. |
• | Timely PCV20 adoption yields significant health and economic benefits in France. |
Abstract |
Objectives |
We assessed the public health and economic impacts in France for infants below 1-year of delaying PCV20 (3 + 1) implementation compared to continuous use of PCV15 (2 + 1) and PCV13 (2 + 1).
Patients and methods |
Population-based Markov model was adapted for French pediatric population. Outcomes included pneumococcal disease cases, deaths, and direct costs. Impact of a PCV20 two-year implementation delay was reported by month, quarter, and year.
Results |
Delaying PCV20 implementation in French children was estimated to result in preventable 15,356 disease cases and 1,489 deaths over two years, with cost of €117.4 million, versus the continuous use of PCV15. PCV20 versus PCV13 results were slightly reduced but followed a similar trend.
Conclusions |
Rapid implementation of PCV20 is estimated to prevent thousands of cases and deaths over two years compared to the continuous PCV15 or PCV13 use, reducing significant negative impact to public health outcomes and waste of health care resources.
Le texte complet de cet article est disponible en PDF.Keywords : Invasive pneumococcal disease, PCV15, PCV20, Pediatric population, Pneumococcal conjugate vaccine
Plan
Vol 55 - N° 5
Article 105084- août 2025 Retour au numéro
Article précédent
- Acute hepatitis E virus infection in adults, Cayenne, French Guiana, 2015–2022
- Clotilde de Colnet, Alolia Aboikoni, Mathieu Nacher, Loïc Epelboin, Céline Michaud, Alexia Barbry, Jacques Izopet, Paul Le Turnier
- Clinical significance of nosocomial Trichosporon asahii in urine: A retrospective cohort study
- Bruno Ali Lopez Luis, Karla alhelí León-Palacios, Araceli Acosta-Ruiz, Ana Maria Gonzalez-Cardel, Graciela Rodriguez-Zuñiga
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?